Truveta’s Post

For researchers dedicated to advancing #treatment for patients with #prostate #cancer, Truveta provides the most complete, timely, and clean regulatory-grade #EHRdata for scientifically rigorous research. You can discover more for yourself below 👇👇 #oncologydata #rwd #rwe #heor #outcomesresearch

🌟 Breaking news: Farletuzumab Ecteribulin shines as a well-tolerated antibody-drug conjugate in #OvarianCancer! 🎗️💊 Ovarian cancer starts in the ovary, fallopian tube, or peritoneum and develops due to the uncontrolled growth of abnormal cells in these regions. Ovarian cancer is often diagnosed at advanced stages, making the treatment difficult. The quest for more effective therapies continues, even though surgery and chemotherapy remain the standard treatments. A fascinating advancement in the treatment of ovarian cancer is the combination of farletuzumab with eribulin. This conjugate has the potential to enhance outcomes for patients with ovarian cancer, particularly those who have developed resistance to conventional therapies. For more informations read our blog @ https://lnkd.in/giD3zbkA and raise awareness about this groundbreaking advancement in ovarian cancer care. 💛 #OvarianCancerAwareness #FarletuzumabEcteribulin #MedicalAdvancements #FightAgainstCancer #MonoclonalAntibody #OvarianCancerSymptoms #OvarianCancerDiagnosis #FarletuzumabEcteribulin #AntibodyDrugConjugate #ADC #OvarianCancerTreatment #OvarianCancerManagement #OvarianCancerCauses #Bhimar #LifeSciences #Healthcare #Informations #Omics #Oncology #Neurology

Do you have a professional interest in bladder cancer, colon cancer, ovarian cancer or pancreatic cancer and how they are treated? Then tune into our Spotify podcast, Combat Innovators: The Present and Future of Cancer Treatment (also available on our YouTube channel). It features in-depth interviews with some of the world’s top clinicians in the areas of urology and surgical oncology.   Link in comments below ⬇ ⬇   NB If you’d like to be featured in a future interview, please DM me   #medicalinnovation #HIPEC #ovariancancer #coloncancer #pancreaticcancer #HIVEC #bladdercancer #CombatMedical

New Therapy Protocol for Colorectal Cancer – Over 50% Had Complete Response! 🙌 Precision Cancer Medicine specialist, Alex Rolland, discusses a recent study that is bringing hope to many patients with locally advanced colorectal cancer – by giving them a much higher chance at long-term remission. Alex explains the exciting results of the TORCH study, which found that adding a combination of certain therapies prior to surgery made a massive difference to the numbers of colon cancer patients achieving remission. Watch this video to learn 👇 ✅ Issues with biomarkers in standard care – and how to get past them? ✅ Colorectal cancer and this new therapy ✅ What is the current standard of care for colorectal cancer? ✅ Adding this new therapy to standard chemo / radiation ✅ The importance of a pCR after neoadjuvant therapy ✅ Exploring the recent TORCH study ✅ Understanding the results of the TORCH study ✅ Summary of these groundbreaking study results ✅ How patients can get the information and support they need now Click to watch 👉 https://buff.ly/4fVXyG8 👀 Alex also explains why patients who achieve a pCR with this new protocol can expect to be cancer-free for 10 years or more. This is compared to only 15% of those who receive the current standard of care and have the same response. He is joined by Precision Oncology Advocate and CTOAM cofounder, Michelle Morand. Together they share next steps patients can take to find out whether this new protocol can work for them and how to access it. #HopeIsHere #PrecisionCancerMedicine

🌍🔬 Insightful Discussion on Prostate Cancer Bone Metastasis at #ESMO2024 At the 2024 ESMO Congress, our colleague El Bachir MOURABIT had the pleasure of interviewing Prof. Silke Gillessen on the challenges and opportunities in managing prostate cancer with bone metastasis. We explored key topics, such as: 🔹 The importance of multidisciplinary collaboration in the comprehensive management of patients. 🔹 Clinical manifestations and early detection methods of bone metastasis in prostate cancer. 🔹 Insights from the EORTC-GUCG 1333/PEACE-3 study on the efficacy of enzalutamide combined with Radium-223 (Ra223) therapy. The dialogue highlighted the potential for improving treatment outcomes through collaboration and innovative therapies. #Oncology #ProstateCancer #BoneMetastasis #ESMO2024 #Urology #CancerResearch #Ra223 #MultidisciplinaryCare #CancerTreatment

📢 Excited to share our latest research on improving prognostic systems for metastatic renal cell carcinoma (mRCC)! Our study demonstrates that a simple RBC-based score, incorporating anaemia, mean corpuscular volume, and red cell distribution width, can significantly predict overall survival in mRCC patients treated with second-line nivolumab. By identifying patients with better prognosis, this score could be integrated into existing prognostic models, allowing for more tailored treatment approaches. This research underscores the importance of refining prognostic tools to enhance patient stratification and guide therapeutic decisions. We’re hopeful this will pave the way for better outcomes in mRCC management. https://lnkd.in/e6gvTtF7 #Oncology #CancerResearch #mRCC #PrecisionMedicine #Immunotherapy #HealthcareInnovation International Urology Cancer Summit OncoAlert OncoViews

Have you tuned into our Medical Innovators’ interviews on our YouTube channel?   They take a deep dive into different aspects of treatments and innovation in bladder cancer, colon cancer, ovarian cancer and pancreatic cancer – all fields where our Combat HIVEC® and HIPEC treatments are currently being used. You’ll get the lowdown from some of the world’s top clinicians in urology and surgical oncology – definitely worth catching up with!   If you prefer to read than listen, all the interviews are also in the blog section of our website.   Links in comments below 🔽   PS If you’d like to share your own experiences and insight, please DM me #medicalinnovation #bladdercancer #peritonealcancer #pancreaticcancer #ovariancancer #coloncancer #HIVEC #HIPEC #CombatMedical

March is Brain Tumour Awareness Month 📣 🧠 And we are passionate about bringing you the latest news & updates - take a look at this NEW: #ESMO2023 interview | The role of #liquidbiopsy in #braincancers 🇪🇸 🎥 Enrico Franceschi, MD, IRCCS Istituto delle Scienze Neurologiche di Bologna, discusses the importance of obtaining #liquidbiopsies in patients with #braintumors 💉 #Liquidbiopsy is fundamental in the treatment of many #cancers for assessing individual #cancerbiology and treatment options, but this is more difficult in #braintumors due to the limited delivery of #circulatingtumorDNA (#ctDNA) across the blood-brain barrier 🩸 🧠 Although #cerebrospinalfluid is a more suitable prognostic assessment tool in these cancers, it is harder to obtain, meaning novel methods of accessing #ctDNA and disrupting the blood-brain barrier are required💡 Take a look 👉 https://lnkd.in/dEHKcpc4 #Oncology #BrainTumourAwarenessMonth ESMO - European Society for Medical Oncology

In this video, Vitaly Margulis, MD, discusses the significance of a 100% biochemical recurrence-free rate at 2 years, and what this means for patients with high-risk localized prostate cancer. #PCSM #AUA24 https://lnkd.in/ePq8P25m

According to the National Cancer Institute, more than 1️⃣0️⃣8️⃣K women in the U.S. are expected to be diagnosed with a gynecological cancer in 2024. Our experts, who work on six sub specialties, recognize the uniqueness of each diagnosis. As the only NCI-designated cancer center in South Florida, we have the largest portfolio of clinical trials, the most advanced approaches to surgery and #CancerResearch. Every new #gynecologic cancer patient's case is presented at a #multidisciplinary tumor board that includes the input of medical, gynecologic and radiation oncologists, radiologists, pathologists and genetic counselors. This collaboration ensures an accurate, comprehensive diagnosis and the most targeted, individualized treatments. You don't have to face #GynecologicCancer alone. We're here to stand with 🙌. Learn more: https://loom.ly/j40NPzQ. #GynecologicCancerAwarenessMonth